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INTRODUCTION 
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INTRODUCTION 
Diabetes mellitus is a common endocrine disorder which involves 
multiple organ systems and leads to significant morbidity and mortality due to 
its accompanying complications. 
The metabolic dysregulation associated with Diabetes mellitus causes 
secondary pathophysiologic changes in multiple organ systems that impose a 
tremendous burden on the individual with diabetes and on the health care 
system.2 
           Diabetes mellitus has been defined as "A metabolic syndrome 
characterised by chronic hyperglycaemia and disturbance of carbohydrate, fat 
and protein metabolism associated with absolute or relative deficiency in  
insulin secretion and or insulin action". 
Much has been accomplished in the field of diabetes but what has been 
troubling one and all are the large macrovascular and micro vascular 
complications of diabetes involving kidneys, eyes, blood vessels, nerves and 
heart. Thyroid diseases are also a common endocrinopathy seen in the adult 
population.  
The present work is a modest attempt to study the prevalence of thyroid 
disorders in patients with type2 Diabetes mellitus. 
           With an increasing incidence worldwide, Diabetes mellitus will be likely 
a leading cause of morbidity and mortality in the future. 
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           Diabetes mellitus is classified on the basis of the pathogenic process that 
leads to hyperglycemia, as opposed to earlier criteria such as age of onset or 
type of therapy. There are two broad categories of DM,designated as type 1 and 
type 2. There is also increasing recognition of other forms of diabetes in which 
the pathogenesis is better understood. 
           Type 1 DM is the result of complete or near-total insulin Deficiency and 
Type 2 DM is a heterogeneous group of disorders characterized by variable 
degrees of insulin resistance, impaired insulin secretion, and increased glucose 
production. 
        
 
 
 
                             
 
                                  
 
 
 
  
 
 
 
AIMS AND OBJECTIVES 
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AIM OF THE STUDY 
1. To study the prevalence of thyroid disorders in patients with  
type 2 diabetes mellitus and non diabetic population. 
 
2. To study the distribution of thyroid disorders in patients with  
type 2 diabetes mellitus regarding age, sex, duration of diabetes, type of 
treatment, family history of diabetes mellitus. 
 
3. To evaluate the relationship between glycemic control and occurrence of 
altered thyroid function in patients with type 2 diabetes mellitus. 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
Diabetes mellitus is characterised by chronic hyperglycemia with 
disturbances of carbohydrate, fat, and protein metabolism due to defects in 
insulin secretion, insulin action, or both1. The metabolic dysregulation 
associated with Diabetes mellitus causes many secondary pathophysiologic 
changes in multiple organ systems that impose a tremendous burden on the 
individual with diabetes and on the health care system.2 
PROBLEM STATEMENT 
A recent study by the World Health Organization (WHO) estimated that 
the worldwide prevalence of diabetes in 2002 was 170 million, with the 
number predicted to grow upto 366 million or more by 2030. The major 
underlying causes are thought to be due to sedentary lifestyle, the consumption 
of non-traditional foods, and a genetic predisposition to the disease. India has 
the largest number of people suffering from diabetes mellitus. 
United Nations in 2006 stated that “diabetes is a chronic, debilitating 
and costly disease associated with severe complications, which poses severe 
risks for families, Member States and the entire world.7 
HISTORY 
Diabetes is as old as medicine. Early evidence of description of 
symptoms of diabetes recorded in the Ebers papyrus, 1550 B.C.8  Arateus  
(30-90 AD), coined the term diabetes, meaning “siphon,” to explain the 
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“liquefaction of the flesh and bones into urine”. In Greek this word means 'to 
run through' that describes 'unquenchable thirst' seen in association with this 
disease. Shushruta (Circa 600AD) noted this disease in Ayurveda and 
described it as "Madhumeha". 10 
In 1869, Paul Langerhans, published in his dissertation on pancreatic 
histology described “clumps of cells,” which were named the islets of 
Langerhans shortly after his death.11,12  In 1889, Minkowski and Von Mering, 
in Strassburg, Germany, discovered the central role of the pancreas in 
diabetes.13  In 1910, Jean de Meyer suggested that the pancreatic secretion 
lacking in diabetic state to be called as “Insulin” to denote its origin from 
insulae of Langerhans.14  Banting and Charles Best in 1921, extracted insulin 
from dog's pancreas.15 
             The first chemical application of insulin was on 14 year old Leon and 
Thompson, a patient of diabetic ketoacidosis in January 1922 in Canada. This 
discovery revolutionized the management of diabetes. Oral hypoglycaemic 
drugs were introduced by Frank and Fuchs in 1955.8 
DESCRIPTION OF DIABETES MELLITUS 
When fully expressed, diabetes is characterized by fasting 
hyperglycemia, but the disease can also be recognized during less overt stages, 
mostly by the presence of glucose intolerance. 
Diabetes can present with characteristic symptoms such as thirst, 
polyuria, blurring of vision, weight loss and polyphagia. Hyperglycemia 
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sufficient to cause pathologic functional changes may quite often be present for 
a long time before the diagnosis is made.1 
Patients may revert to having impaired glucose regulation or even 
normal glycemia, particularly in recent-onset type 2 diabetes.16  
In type 1 diabetes, after a short period of insulin treatment, there may be 
a variable period when insulin is no longer required for survival and glucose 
tolerance may improve, the so-called honeymoon period. Eventually such 
patients do need insulin treatment for survival.17 
ETIOLOGIC CLASSIFICATION OF DIABETES MELLITUS 
I.Type 1 diabetes (beta cell destruction, usually leading to absolute insulin 
deficiency) 
A. Immune-mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly insulin secretory defect with 
insulin resistance) 
III. Other specific types of diabetes 
A. Genetic defects of beta cell development or function characterized by 
mutations in: 
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1. Hepatocyte nuclear transcription factor (HNF) 4α (MODY 1) 
2. Glucokinase (MODY 2) 
3. HNF-1α (MODY 3) 
4. Insulin promoter factor-1 (IPF-1; MODY 4) 
5. HNF-1β (MODY 5) 
6. NeuroD1 (MODY 6) 
7. Mitochondrial DNA 
8. Subunits of ATP-sensitive potassium channel 
9. Proinsulin or insulin 
10. Other pancreatic islet regulators/proteins such as KLF11,  
       PAX4, BLK, GATA4, GATA6, SLC2A2 (GLUT2), RFX6, GLIS3 
B. Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipodystrophy syndromes 
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C. Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy, 
mutations in carboxyl ester lipase 
D. Endocrinopathies—acromegaly, Cushing’s syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, 
aldosteronoma. 
E. Drug- or chemical-induced—glucocorticoids, vacor (a rodenticide), 
pentamidine, nicotinic acid, diazoxide, β-adrenergic agonists, thiazides, 
calcineurin and mTOR inhibitors, hydantoins, asparaginase, α-interferon, 
protease inhibitors, antipsychotics (atypicals and others), epinephrine. 
F. Infections—congenital rubella, cytomegalovirus, coxsackievirus. 
G. Uncommon forms of immune-mediated diabetes—“stiff-
personsyndrome, anti-insulin receptor antibodies 
H. Other genetic syndromes sometimes associated with diabetes- 
Wolfram’s syndrome, Down’s syndrome, Klinefelter’s syndrome, Turner’s 
syndrome, Friedreich’s ataxia, Huntington’s chorea, Laurence-Moon- Biedl 
syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome. 
IV. Gestational diabetes mellitus (GDM). 
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The majority of cases of diabetes fall into two broad etiopathogenetic 
categories, now called type 1 and type 2 diabetes. 
TYPE 1 DIABETES MELLITUS 
Type 1 diabetes is the form of the disease due primarily to β-cell 
destruction in which insulin is required for survival. It is characterized by the 
presence of anti-GAD, anti-islet cell, or antiinsulin antibodies, which reflects 
the autoimmune processes that have led to β-cell destruction. 
TYPE 2 DIABETES MELLITUS 
Type 2 diabetes is the most common form of diabetes. Insulin resistance 
and abnormal insulin secretion are central to the development of type 2 DM.2 
Patients with type 2 diabetes usually have insulin resistance and relative, rather 
than absolute, insulin deficiency and are associated with progressive β-cell 
failure with increasing duration of diabetes.20  The risk of developing type 2 
diabetes increases with age, obesity, physical inactivity and family history of 
diabetes.1  The disease can occur at any age and is now seen in children and 
adolescents.21 
Diagnostic criteria for the diagnosis of diabetes mellitus 
•Symptoms of diabetes plus random blood glucose concentration                               
≥11.1 mmol/L (200 mg/dL) or 
• Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) or 
• Hemoglobin A1c ≥ 6.5%c or 
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• 2-hr plasma glucose ≥11.1 mmol/L (200 mg/dL) during an oral glucose 
    tolerance test. 
Random - defined as without regard to time since the last meal.  
Fasting - defined as no caloric intake for at least 8 h.  
Hemoglobin A1c test - should be performed in a laboratory using a 
method approved by the National Glycohemoglobin Standardization Program 
and correlated to the reference assay of the Diabetes Control and 
Complications Trial. hemoglobin A1c should not be used for diagnostic 
purposes.  
OGTT - The test should be performed using a glucose load containing 
the equivalent of 75 g anhydrous glucose dissolved in water, not recommended 
for routine clinical use. 
Note: In the absence of unequivocal hyperglycemia and acute metabolic 
decompensation,these criteria should be confirmed by repeat testing on a 
different day. 
Source: Adapted from American Diabetes Association: Diabetes Care 
37(Suppl 1):S14,2014. 
               The current criteria for the diagnosis of DM emphasize the HbA1c or 
the FPG as the most reliable and convenient tests for identifying DM in 
asymptomatic individuals (however, some individuals may meet criteria for 
11 
 
one test but not the other).OGTT, although still a valid means for diagnosing 
DM, is not often used in routine clinical care. 
                 The diagnosis of DM has profound implications for an individual 
from both a medical and a financial standpoint. Thus, abnormalities on 
screening tests for diabetes should be repeated before making a definitive 
diagnosis of DM, unless acute metabolic derangements or a markedly elevated 
plasma glucose are present. 
IMPAIRED GLUCOSE TOLERANCE 1 
Defined as 2 hours values in the oral glucose tolerance test (OGTT) 
between 140 and 199mg/dl (7.8 and 11.1 mmol/L). Glucose tolerance is above 
the conventional normal range but lower than the level diagnostic of diabetes. 
Persons with IGT have a high risk of developing diabetes and arterial disease. 
IGT is more frequent in obese persons and often is associated with 
hyperinsulinemia and insulin resistance. 
IMPAIRED FASTING GLUCOSE 1 
Defined as fasting plasma glucose concentrations of 100 to 125 mg/dL 
(5.6 to <7.0 mmol/L). IFG is also a stage of impaired glucose homeostasis with 
fasting glucose levels were above normal but below those diagnostic for 
diabetes. 
Risk Factors for Type 2 Diabetes Mellitus 
 Family history of diabetes (i.e., parent or sibling with type 2 diabetes) 
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 Obesity (BMI ≥25 kg/m2 or ethnically relevant definition for 
overweight) 
 Physical inactivity 
 Race/ethnicity (e.g., African American, Latino, Native American, Asian 
 American, Pacific Islander) 
 Previously identified with IFG, IGT, or an hemoglobin A1c of 5.7–6.4% 
 History of GDM or delivery of baby >4 kg (9 lb) 
 Hypertension (blood pressure ≥140/90 mmHg) 
 HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride 
level >250 mg/dL (2.82 mmol/L) 
 Polycystic ovary syndrome or acanthosis nigricans 
 History of cardiovascular disease. 
SCREENING FOR DIABETES MELLITUS 
The ADA recommends screening all individuals >45 years every 3 years 
and screening individuals at an earlier age if they are overweight (BMI >25 
kg/m2 or ethnically relevant definition for overweight) and have one additional 
risk factor for diabetes. 
ACUTE COMPLICATIONS OF DM2 
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state 
(HHS) are acute complications of diabetes. DKA primarily occurs in type 1 
DM but, can also occur in type 2 DM. HHS is primarily seen in individuals 
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with type 2 DM. Both disorders are associated with absolute or relative insulin 
deficiency, volume depletion, and acid-base abnormalities. 
CHRONIC COMPLICATIONS OF DM 2 
The vascular complications of DM are divided into microvascular 
(retinopathy, neuropathy, nephropathy) and macrovascular complications 
[coronary artery disease (CAD), peripheral arterial disease (PAD), 
cerebrovascular disease]. Nonvascular complications include problems such as 
gastroparesis, infections, and skin changes. 
             The microvascular complications of both type 1 and type 2 DM result 
from chronic hyperglycemia. Evidence implicating a causative role for chronic 
hyperglycemia in the development of macrovascular complications were 
inconclusive. Other factors (dyslipidemia and hypertension) also play 
important roles in macrovascular complications. 
THYROID 
The thyroid (Greek thyreos, shield, plus eidos, form) consists of two 
lobes that are connected by an isthmus. It is located anterior to the trachea 
between the cricoid cartilage and the suprasternal notch. Four parathyroid 
glands, which produce parathyroid hormone are located posterior to each pole 
of the thyroid.27 
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The normal thyroid gland secretes sufficient amounts of the thyroid 
hormones triiodothyronine (T3) and tetraiodothyronine (T4, thyroxine) to 
normalize growth and development, body temperature, and energy levels. 
Calcitonin, the second type of thyroid hormone, is important in the 
regulation of calcium metabolism.28 
BIOSYNTHESIS OF THYROID HORMONES 27 
          Iodide, ingested from food, water, or medication, is rapidly absorbed 
from intestine and enters an extracellular fluid pool. Transport of iodide into 
the thyroid gland is by an intrinsic follicle cell basement membrane 
sodium/iodide symporter (NIS). At the apical cell membrane a second  
I- transport enzyme called pendrin is present. Iodide is oxidized by thyroidal 
peroxidase to iodine that rapidly iodinates tyrosine residues within the 
thyroglobulin molecule to form monoiodotyrosine (MIT) and diiodotyrosine 
(DIT). This process is called iodide organification.Two molecules of DIT 
combine within the thyroglobulin molecule to form L-thyroxine (T4). One 
molecule of MIT and one molecule of DIT combine to form T3. T4, T3, MIT, 
and DIT are released from thyroglobulin by exocytosis and proteolysis of 
thyroglobulin at the apical colloid border. Most of the hormone released is 
thyroxine. Most of the T3 circulating in the blood is derived from peripheral 
metabolism of T4.                    
Both hormones are bound to plasma proteins, including thyroxine 
binding globulin (TBG); transthyretin (TTR); and albumin. The plasma binding 
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proteins increase the pool of circulating hormone, delay hormone clearance, 
and may modulate hormone delivery to selected tissue sites. 
 
DEIODINASES 27 
T4 is converted to T3 by the deiodinase enzyme. 
1. Type I deiodinase, which is located primarily in thyroid, liver, and 
kidney, has a relatively low affinity for T4. 
2. Type II deiodinase has a higher affinity for T4 and is found primarily in 
the pituitary gland, brain, brown fat, and thyroid gland. 
3. Type III deiodinase inactivates T4 and T3 and is the most important 
source of reverse T3 (r T3) 
PHYSIOLOGICAL EFFECTS OF THYROID HORMONES 29 
Heart     :         Increases number of β adrenergic receptors 
                     Enhances response to catecholamines 
Adipose tissue  :   Stimulate lipolysis 
Muscle     :    Increases protein breakdown 
Bone    :  Promote growth and development 
Nervous system  :  Promote normal brain development 
Gut    :  Increases carbohydrate absorption 
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Lipoprotein   :  Stimulate LDL receptors 
Others   :  Increases metabolic rate and oxygen consumption 
 
REGULATION OF THYROID AXIS 27 
The thyroid axis is a classic example of an endocrine feedback loop. 
TRH stimulates pituitary production of TSH, which, in turn, stimulates thyroid 
hormone synthesis and secretion. Thyroid hormones feed back to inhibit TRH 
and TSH production. 
EXOGENOUS AND ENDOGENOUS FACTORS SUPPRESSING TSH 
SECRETION:30 
Dopamine and agonists, Somatostatin, Dobutamine, Glucocorticoids, 
Interleukins, TNF-α, Thyroid hormones and Phenytoin. 
FACTORS ASSOCIATED WITH ALTERED BINDING OF 
THYROXINE BY THYROXINE-BINDING GLOBULIN 30 
Increased Binding: 
Pregnancy, Oral contraceptives, Infectious hepatitis, Cirrhosis, HIV, 
Acute intermittent porphyria and Tamoxifen. 
Decreased Binding 
Androgens, Large doses of glucocorticoids, acromegaly, Nephrotic 
syndrome , Major systemic illness and Psychiatric illness. 
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FACTORS ASSOCIATED WITH DECREASED CONVERSION OF T4 
TO T3: 30 
Fetal life, Caloric restriction, Hepatic disease, Major Systemic illness, 
Propylthiouracil, Glucocorticoids, Propranolol, Iodinated X-ray contrast agents, 
Amiodarone and Selenium deficiency. 
HYPOTHYROIDISM 
Hypothyroidism is the condition resulting from a lack of effects of 
thyroid hormones on body tissues.31 
Symptoms 
1.Tiredness 
2.Weakness 
3.Dry skin  
4.Feeling cold 
5.Hair loss 
6.Difficulty concentrating and poor memory 
7.Constipation 
8.Weight gain with poor appetite 
9.Dyspnea 
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10.Hoarse voice 
11.Menorrhagia (later oligomenorrhea or amenorrhea) 
12.Paresthesia 
 13.Impaired hearing. 
Signs 
1.Dry coarse skin 
2.cool peripheral extremity 
3.Puffy face, hands, and feet (myxedema) 
4.Diffuse alopecia 
5.Bradycardia 
6.Peripheral edema 
7.Delayed tendon reflex relaxation 
8.Carpal tunnel syndrome 
9.Serous cavity effusions.27 
METABOLIC ABNORMALITIES IN HYPOTHYROIDISM 
Hypothyroidism is associated with a reduction in glucose disposal to 
skeletal muscle and adipose tissue and also associated with reduced 
gluconeogenesis. The net effect of these influences is usually minimal on 
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serum glucose levels. Degradation of insulin, is slowed and the sensitivity to 
exogenous insulin may be increased.32  Both the synthesis and the degradation 
of lipid are depressed in hypothyroidism with a net effect of accumulation of 
LDL and triglycerides. HDL concentrations and Plasma free fatty acid levels 
are decreased.33 
SUBCLINICAL HYPOTHYROIDISM 
Defined as a low-normal free T4 but a slightly elevated serum TSH 
level. The TSH elevation in such patients is modest, with values typically 
between 4 and 10 mU/L. Rates of progression to overt hypothyroidism ranges 
from 3% to 8% per year, higher rates seen in individuals with initial TSH 
concentration greater than 10 mU/L and those with positive anti-TPO 
antibodies.34 The association of mild hypothyroidism with an increase in risk 
for atherosclerotic heart disease has been shown by some, but not others.35,36. 
HYPERTHYROIDISM 27 
Hyperthyroidism is a state when thyrotoxicosis occurs because of 
sustained over production of hormones by thyroid gland. 
Symptoms 
1.Heat intolerance and sweating 
2.Palpitation 
3.Fatigue and weakness 
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4.Weight loss with increased appetite 
5.Diarrhea 
6.Polyuria 
7.Oligomenorrhea 
 8.loss of libido. 
Signs 
1.Tachycardia 
2.Atrial fibrillation in the elderly 
3.Tremor 
4.Goiter 
5.Warm, moist skin 
6.Muscle weakness 
7.Proximal myopathy 
8.Lid retraction or lag  
9.Gynaecomastia. 
METABOLIC ABNORMALITIES IN HYPERTHYROIDISM 
Preexisting diabetes mellitus may be aggravated, one cause being 
accelerated turnover of insulin.37  Both lipogenesis and lipolysis are increased 
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in thyrotoxicosis, but the net effect is lipolysis, as reflected by an increase in 
the plasma concentration of free fatty acids and glycerol and a decrease in 
serum cholesterol level. Triglyceride levels are usually slightly decreased.38 
SUBCLINICAL HYPERTHYROIDISM 
There are no signs of thyrotoxicosis but the serum TSH is subnormal 
despite normal serum free T4 concentration.37 Subclinical hyperthyroidism may 
accelerate bone loss in postmenopausal women39 and increases the incidence of 
atrial arrhythmias including atrial fibrillation in elderly patients.31 
DIABETES AND THYROID DISEASES 
Diabetes mellitus and thyroid diseases are the two common 
endocrinopathies seen in the adult population. Insulin and thyroid hormones are 
intimately involved in cellular metabolism. Excess or deficit of either of these 
hormones could result in the functional derangement of the other.40 
EFFECT OF DIABETES ON THYROID FUNCTION 
In euthyroid individuals with diabetes mellitus, the serum T3 levels, 
basal TSH levels and TSH response to thyrotropin releasing hormone (TRH) 
may all be strongly influenced by the glycemic status.41 Poorly controlled 
diabetes, both Type 1 and Type 2, may induce a “Low T3 state” characterized 
by low serum total and free T3 levels, increase in reverse T3 (r T3) but near 
normal serum T4 and TSH concentrations.42 Low serum T3 is due to reduced 
peripheral conversion of thyroxine (T4) to tri-iodothyronine (T3) via 5’ 
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monodeiodination reaction and may normalize with improvement in glycemic 
status but even with good diabetes control, the normal nocturnal TSH peak may 
not be restored in C-peptide negative patients.43 
EFFECT OF DIABETES MELLITUS ON THYROID DISEASES 
Dysthyroid optic neuropathy (DON) resulting in blindness is the most 
threatening complication of Graves’ orbitopathy (GO). It is due to the 
compression of optic nerve by enlarged extraocular muscles at the orbital apex. 
Incidence of DON in patients with diabetes mellitus is higher than that 
seen in control “GO” group and the recovery after treatment is also poor. This 
has been explained by reduced oxygenation of optic nerve in diabetic patient 
owing to the vasculopathy making it more susceptible to the pressure effect.44 
EFFECT OF HYPERTHYROIDISM ON GLYCEMIC STATUS 
Graves disease is the commonest cause of hyperthyroidism. While 
Graves disease may be associated with type 1 diabetes in polyglandular 
autoimmune syndrome, thyrotoxicosis by itself is diabetogenic. Frank diabetes 
occurs in 2-3%, when hyperthyroidism develops in normal individuals. In 
known diabetic patients hyperthyroidism causes deterioration of glycemic 
control status.42 
These changes are due to alteration in following systems:- 
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1. Gastrointestinal System 
In hyperthyroidism, there is accelerated gastric emptying, enhanced 
intestinal glucose absorption and an increase in portal venous blood flow. 
2. Insulin Secretion 
Insulin secretion decreases in hyperthyroidism.45,46  Insulin clearance 
rate is reported to be increased by about 40%.47 Long term thyrotoxicosis has 
been shown to cause beta cell dysfunction resulting in poor insulin response to 
glucose.48 
3. Endogenous Glucose Production 
In hyperthyroidism the endogenous glucose production is greatly 
increased by a variety of mechanisms: (a) there is an increase in the availability 
of gluconeogenic precursors( lactate, glutamine, alanine and FFA) stimulating 
hepatic gluconeogenesis,49  Inhibition of glycogen synthesis,50 
 Upregulation of GLUT-2 glucose transporters protein expression in the 
Hepatocyte,51 Increased secretion and exaggerated effects of glucagon and 
adrenaline on liver cells.49 
4. Glucose utilization 
In adipocytes isolated from rats, the sensitivity of glucose transport and 
utilization to insulin has been found to be normal, increased or decreased.45  In 
skeletal muscle, there is a preferential increase in glucose uptake and lactate 
formation . This is due to increase in GLUT-1 and GLUT-4 transporters,52 
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increased glycogenolysis due to beta adrenergic stimulation49, increased 
activity of hexokinase and 5 phosphofructokinase.53 
Thus the net effect of changes occurring at various levels such as 
gastrointestinal tract, beta cells, hepatocytes, adipocytes and skeletal muscles is 
hyperglycemia. 
EFFECT OF HYPOTHYROIDISM ON GLYCEMIC STATUS 
In hypothyroidism, the synthesis and release of insulin is decreased.46 
The rate of hepatic glucose output is decreased probably due to reduced 
gluconeogenesis. A post receptor defect has been proposed to explain the 
decrease in insulin stimulated glucose utilization in peripheral tissues.49 The net 
effect is an increased risk of recurrent hypoglycemia in a diabetic individual.54 
ASSOCIATION BETWEEN DIABETES MELLITUS AND THYROID 
DISORDERS: 
Celani MF et al in their study found that abnormal TSH values in type 2 
diabetic patients found before tight glycemic control reverted to normal values 
with adequate treatment of diabetes with OHA or insulin. They suggested that 
the diagnosis of thyroid dysfunction in type 2 diabetes should be delayed until 
improvement of metabolic status.55 
Proces S et al in their study found that in diabetic patients TSH was 
lower than in non diabetic subjects. They concluded that besides known 
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parameters such as age and drugs, thyroid function tests can also be altered in 
diabetes mellitus and obesity.56 
Warren RE et al in their study found that serum thyrotropin (i.e. baseline 
TSH) is a better predictor of thyroid dysfunction than thyroid autoantibodies in 
people with diabetes.57 
Vondra K et al in their study found that prevalence of thyroid disease in 
diabetic patients is 2-3 times higher than in non diabetic subjects. It raises with 
age and is strongly influenced by female gender and autoimmune diabetes. 
They even recommended thyroid disease screening and diagnosis in patients 
with diabetes mellitus.58 
        Abdel Rahman et al in their study found that overall prevalence of thyroid 
diseases was 12.5% in type 2 diabetes mellitus group. The study suggested that 
diabetic patients should be screened for asymptomatic thyroid dysfunction.59 
Perros P et al in their study found that the prevalence of thyroid disease was 
13.4% in a randomly selected group of 1310 adult diabetic patients attending a 
diabetic clinic. They suggested that thyroid function should be screened 
annually in diabetic patients to detect asymptomatic thyroid dysfunction which 
is increased in frequency in a diabetic population.60 
Smithson MJ in his study found that the prevalence of thyroid disease 
(previously known and diagnosed as a result of screening) in the entire 
population of diabetic patients in his sample of 4300 general practice patients 
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was 10.8%. He concluded by suggesting that screening for thyroid disease 
should be considered in patients receiving diabetes care in community.61 
Zdrojewicz Z et al in their study found that there was no difference in 
thyroid gland function in patients with non insulin dependent diabetes 
mellitus(type 2) and different therapies have no influence on thyroid gland 
function.62 
           Parr JH et al in their study found that improvement in long term 
metabolic control did not influence free thyroid hormone levels in well 
controlled and moderately-poor controlled diabetics taking insulin.63 
          Chubb SA et al in their study found that none of those patients with type 
2 diabetes diagnosed of subclinical hypothyroidism has overt hypothyroidism 
when restudied after 5 years. So they concluded that subclinical 
hypothyroidism is a common but incidental finding and routine screening of 
thyroid function in type 2 diabetes is questionable.64 
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MATERIALS AND METHODS 
The present study titled "PREVALENCE OF THYROID  
DYSFUNCTION IN TYPE 2 DIABETIC AND NON DIABETIC 
POPULATION " was carried out in the Department of Internal Medicine and 
in the Department of Diabetology, Rajiv Gandhi Government General Hospital 
and Madras medical college , Chennai. 
1. Study design  :  Cross sectional study. 
2. Period of study :  April 2018 to September 2018 
3. Materials   :  Questionnaire, Blood pressure, CBC,FBS, 
PPBS, RFT,LFT, Urinalysis, ECG,  
Chest X ray, Thyroid profile (FT3, FT4  
and TSH). 
4. Study group  : The study group included 50 persons with   
 known type 2 diabetes mellitus or newly  
 detected Type 2 diabetes mellitus without  
 known thyroid disorders either admitted in  
 wards or attending the outpatient  
 departments and 50 healthy volunteers  
 without history of diabetes mellitus and  
 thyroid disorders who met the inclusion  
 criteria. 
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Inclusion criteria 
All patients in the diabetic group confirmed by fasting blood glucose 
levels >126 mg/dl, post prandial blood glucose levels >200 mg/dl on more than 
two occasions based on the American Diabetes Association (ADA) criteria for 
diagnosis of Diabetes mellitus. 
Age- and sex-matched healthy volunteers without a history of diabetes 
and with normal blood sugar were considered to be control subjects. 
Exclusion criteria 
1.Type 1 DM 
2.Known thyroid dysfunction 
3.Liver disease 
4.Renal disease 
5.Pregnancy 
6.Hypertension 
7. Patients not willing for study  
All patients in the study group were selected without any bias for sex, 
duration, severity or control of diabetes. A thorough history was recorded with 
particular emphasis on symptoms of hypothyroidism and hyperthyroidism. The 
presence of associated illness like coronary artery disease, hypertension and 
cerebrovascular accident were noted. Family history regarding diabetes 
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mellitus and treatment history of oral hypoglycaemics or insulin along with 
duration was also included. 
Statistical Analysis Plan :  
Data analysed using statistical package - SPSS Software  
Consent:  
All participants / attenders gave written informed consent.  
Ethical Committee Approval:  
Institutional Ethics Committee of Madras Medical College approved the 
study. 
Blood sugar 
Both fasting and postprandial blood sugar are estimated by glucose 
oxidase and peroxidase (GOD–POD) method. 
Thyroid Profile 
Estimation done in fasting serum sample. 
Methods used: 
1.TSH - Ultrasensitive sandwich chemi luminescent immuno assay 
2. FT3 & FT4 - Competitive chemi luminescent immuno assay. 
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Renal function test 
The Blood Urea in this study was estimated using DAM method 
(Diacetyl Monoxime). Serum creatinine was estimated using Modified Jaffe’s 
method. 
Urinalysis 
Urine sample is collected for urine routine analysis which includes 
sugar, protein, cytology and urinary sediments 
Thyroid profile 
Reference values: FT3 : 3.1-6.8 pmol/L ,TSH : 0.3-4.2mcgIU/mL, FT4 : 
0.93- 1.7 ng/dL. Overt hypothyroidism is defined as TSH >10 mcgIU/mL with 
FT4 < 0.93 ng/ dL. 
Subclinical hypothyroidism is defined as TSH > 4.5 mcgIU/ml with 
normal FT3 and FT4 levels Overt hyperthyroidism is defined as TSH < 0.3 
mcgIU/mL with FT4 > 1.7 ng/dL 
Subclinical hyperthyroidism is defined as TSH < 0.3 mcgIU/mL with 
normal FT3 and FT4 levels. 
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RESULTS AND ANALYSIS 
                                 AGE DISTRIBUTION OF CASES                                     
                                                             
Table-1 
Frequency Table 
 
AGE GROUP Frequency Percent 
30-40 YEARS 8 8.0 
41-50 YEARS 44 44.0 
51-60 YEARS 37 37.0 
61-70 YEARS 11 11.0 
Total 100 100.0 
 
AGE GROUP -  DIABETIC YES/NO 
Cross tabulation 
 
DIABETICYESNO 
Total 
YES NO 
AGE_GROUP 
30-40 YEARS 
Count 4 4 8 
% 8.0% 8.0% 8.0% 
41-50 YEARS 
Count 12 32 44 
% 24.0% 64.0% 44.0% 
51-60 YEARS 
Count 24 13 37 
% 48.0% 26.0% 37.0% 
61-70 YEARS 
Count 10 1 11 
% 20.0% 2.0% 11.0% 
Total 
Count 50 50 100 
% 100.0% 100.0% 100.0% 
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 Distribution of Cases According to Gender 
Table-2 
GENDER Frequency Percent 
MALE 52 52.0 
FEMALE 48 48.0 
Total 100 100.0 
 
 
 
 
                
 
 
52%
48%
GENDER
MALE
FEMALE
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Distribution According to Duration of Diabetes Mellitus 
Table-3 
DURATION OF DM 
IN YEARS 
Frequency Percent 
1.00 2 4.0 
2.00 5 10.0 
3.00 12 24.0 
4.00 12 24.0 
5.00 11 22.0 
6.00 4 8.0 
7.00 4 8.0 
Total 50 100.0 
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DURATION_GROUP Frequency Percent 
UP TO 2 YEARS 7 14.0 
2-4 YEARS 24 48.0 
ABOVE 4 YEARS 19 38.0 
Total 50 100.0 
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24%
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YEARS OF DIABETIC
UP TO 2 YEARS
2-4 YEARS
ABOVE 4 YEARS
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DISTRIBUTION ACCORDING TO REGULARITY OF TREATMENT 
Table-4 
TREATMENT Frequency Percent 
IRREGULAR 13 26.0 
REGULAR 37 64.0 
Total 50 100.0 
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38 
 
 
DISTRIBUTION ACCORDING TO FAMILY HISTORY OF  
DIABETES MELLITUS 
Table-5 
FAMILY H/O DM Frequency Percent 
YES 32 64.0 
NO 18 36.0 
Total 50 100.0 
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DISTRIBUTION OF CASES ACCORDING TO ABNORMAL  
THYROID PROFILE 
Table-6 
THYROID FUNCTION Number Percentage 
With Normal Thyroid Profile 35 70 
With Abnormal Thyroid Profile 15 30 
Total 50 100.0 
 
The above table shows 30% (15/50) of the patients with diabetes 
mellitus in the study group had abnormal thyroid profile and 70% of patients 
had normal thyroid profile. 
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DISTRIBUTION OF THYROID DISEASES 
Table-7 
Thyroid Profile Number of cases Percentage 
Normal 35 70 
Overt Hypothyroidism 7 14 
Subclinical Hypothyroidism 4 8 
Overt Hyperthyroidism 2 4 
Subclinical Hyperthyroidism 2 4 
Total 50 100 
 
The above table shows that among the 30% of abnormal thyroid profile 
14% had overt hypothyroidism,8% had subclinical hypothyroidism,4% had 
overt hyperthyroidism and 4% had subclinical hyperthyroidism. 
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ABNORMAL THYROID PROFILE VS AGE GROUP 
Table-8a 
Crosstab 
 FT3 Total 
LOW NORMAL HIGH 
AGE_ 
GROUP 
30-40 YEARS 
Count 2 6 0 8 
% within FT3 28.6% 6.6% 0.0% 8.0% 
41-50 YEARS 
Count 3 40 1 44 
% within FT3 42.9% 44.0% 50.0% 44.0% 
51-60 YEARS 
Count 2 34 1 37 
% within FT3 28.6% 37.4% 50.0% 37.0% 
61-70 YEARS 
Count 0 11 0 11 
% within FT3 0.0% 12.1% 0.0% 11.0% 
Total 
Count 7 91 2 100 
% within FT3 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=5.423 P=0.491 
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Table-8b 
CROSSTAB 
Age 
group 
FT4 Total 
LOW NORMAL HIGH 
 
30-40 YEARS 
Count 2 6 0 8 
%   FT4 28.6% 6.6% 0.0% 8.0% 
41-50 YEARS 
Count 3 40 1 44 
%   FT4 42.9% 44.0% 50.0% 44.0% 
51-60 YEARS 
Count 2 34 1 37 
%   FT4 28.6% 37.4% 50.0% 37.0% 
61-70 YEARS 
Count 0 11 0 11 
%   FT4 0.0% 12.1% 0.0% 11.0% 
Total 
Count 7 91 2 100 
%   FT4 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=5.423  P=0.491 
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Table-8c 
Age 
Group 
TSH Total 
LOW NORMAL HIGH 
 
30-40 YEARS 
Count 0 6 2 8 
%   TSH 0.0% 7.1% 16.7% 8.0% 
41-50 YEARS 
Count 2 38 4 44 
%   TSH 50.0% 45.2% 33.3% 44.0% 
51-60 YEARS 
Count 1 30 6 37 
%   TSH 25.0% 35.7% 50.0% 37.0% 
61-70 YEARS 
Count 1 10 0 11 
%   TSH 25.0% 11.9% 0.0% 11.0% 
Total 
Count 4 84 12 100 
%   TSH 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=4.733 P=0.579 
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ABNORMAL THYROID PROFILE VS GENDER 
Table-9a 
 FT3 Total 
LOW NORMAL HIGH 
GENDER 
MALE 
Count 3 48 1 52 
% within FT3 42.9% 52.7% 50.0% 52.0% 
FEMALE 
Count 4 43 1 48 
% within FT3 57.1% 47.3% 50.0% 48.0% 
Total 
Count 7 91 2 100 
% within FT3 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.258  P=0.879 
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TABLE-9B 
 FT4 Total 
LOW NORMAL HIGH 
GENDER 
MALE 
Count 3 48 1 52 
%   FT4 42.9% 52.7% 50.0% 52.0% 
FEMALE 
Count 4 43 1 48 
%   FT4 57.1% 47.3% 50.0% 48.0% 
Total 
Count 7 91 2 100 
%   FT4 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.258 P=0.879 
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TABLE-9C 
 TSH Total 
LOW NORMAL HIGH 
GENDER 
MALE 
Count 2 44 6 52 
%   TSH 50.0% 52.4% 50.0% 52.0% 
FEMALE 
Count 2 40 6 48 
%   TSH 50.0% 47.6% 50.0% 48.0% 
Total 
Count 4 84 12 100 
%   TSH 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=0.031 P=0.985 
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Thyroid Profile In Type 2 Diabetic and Non Diabetic patients 
Table-10a 
 FT3 Total 
LOW NORMAL HIGH 
DIABETIC 
YES/NO 
YES 
Count 7 41 2 50 
% within 
FT3 
100.0% 45.1% 100.0% 50.0% 
NO 
Count 0 50 0 50 
% within 
FT3 
0.0% 54.9% 0.0% 50.0% 
Total 
Count 7 91 2 100 
% within 
FT3 
100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=9.890* P=0.007 
The above table depicts that 50 diabetes patients and 50 normal patients. 
among the 7 low t3,all 7(100%) and 2 high t3,all 2(100%) were belongs to 
diabetic patients. The chi square value was 9.89 which were highly significant 
which tells that there is association between t3 values and diabetes. 
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Table-10b 
 FT4 Total 
LOW NORMAL HIGH 
DIABETIC 
YES/NO 
YES 
Count 7 41 2 50 
%   FT4 100.0% 45.1% 100.0% 50.0% 
NO 
Count 0 50 0 50 
%   FT4 0.0% 54.9% 0.0% 50.0% 
Total 
Count 7 91 2 100 
%   FT4 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=9.890* P=0.007 
The above table depicts that 50 diabetes and 50 normal controls. among 
the 7 low t4 patients, all 7(100%) and 2 high t4,all 2(100%) were belongs to 
diabetic patients. The chi square value was 9.89 which were highly significant 
which tells that there is association between t4 values and diabetes. 
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Table-10c 
 TSH Total 
LOW NORMAL HIGH 
DIABETIC 
YES/NO 
YES 
Count 4 35 11 50 
%   TSH 100.0% 41.7% 91.7% 50.0% 
NO 
Count 0 49 1 50 
%   TSH 0.0% 58.3% 8.3% 50.0% 
Total 
Count 4 84 12 100 
%   TSH 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=14.667** P=0.001 
 
The above table depicts that 50 diabetes patients and 50 normal controls. 
Among the 4 low TSH patients all 4(100%) and 11 high TSH,11(92%) were 
belongs to diabetic patients. The chi square value was 14.67 which were highly 
significant which tells that there is association between TSH values and 
diabetes. 
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Abnormal thyroid profile Vs Duration of Diabetes 
Table-11a 
Duration 
Group 
FT3 Total 
LOW NORMAL HIGH 
 
UP TO 2 YEARS 
Count 1 6 0 7 
%   FT3 14.3% 14.6% 0.0% 14.0% 
2-4 YEARS 
Count 3 19 2 24 
%   FT3 42.9% 46.3% 100.0% 48.0% 
ABOVE 4 YEARS 
Count 3 16 0 19 
%   FT3 42.9% 39.0% 0.0% 38.0% 
Total 
Count 7 41 2 50 
%   FT3 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=2.286 P=0.682 
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Table-11b 
Duration 
group 
FT4 
Total 
LOW NORMAL HIGH 
 
UP TO 2 YEARS 
Count 1 6 0 7 
%   FT4 14.3% 14.6% 0.0% 14.0% 
2-4 YEARS 
Count 3 19 2 24 
%   FT4 42.9% 46.3% 100.0% 48.0% 
ABOVE 4 YEARS 
Count 3 16 0 19 
%   FT4 42.9% 39.0% 0.0% 38.0% 
Total 
Count 7 41 2 50 
%   FT4 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=2.286  P=0.682 
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Table-11c 
Duration 
Group 
TSH Total 
LOW NORMAL HIGH 
 
UP TO 2 YEARS 
Count 0 6 1 7 
%   TSH 0.0% 17.1% 9.1% 14.0% 
2-4 YEARS 
Count 3 16 5 24 
%   TSH 75.0% 45.7% 45.5% 48.0% 
ABOVE 4 YEARS 
Count 1 13 5 19 
%   TSH 25.0% 37.1% 45.5% 38.0% 
Total 
Count 4 35 11 50 
%   TSH 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=2.002 P=0.735 
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Abnormal thyroid profile Vs Family history of Diabetes 
Table-12a 
Family 
H/O DM 
FT3 Total 
LOW NORMAL HIGH 
 
YES 
Count 4 26 2 32 
%   FT3 57.1% 63.4% 100.0% 64.0% 
NO 
Count 3 15 0 18 
%   FT3 42.9% 36.6% 0.0% 36.0% 
Total 
Count 7 41 2 50 
%   FT3 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=1.274 P=0.529 
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Table-12b 
Family 
H/O DM 
FT4 Total 
LOW NORMAL HIGH 
 
YES 
Count 4 26 2 32 
%   FT4 57.1% 63.4% 100.0% 64.0% 
NO 
Count 3 15 0 18 
%   FT4 42.9% 36.6% 0.0% 36.0% 
Total 
Count 7 41 2 50 
%   FT4 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=1.274  P=0.529 
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Table-12c 
Family 
H/O DM 
TSH Total 
LOW NORMAL HIGH 
 
YES 
Count 4 23 5 32 
%   TSH 100.0% 65.7% 45.5% 64.0% 
NO 
Count 0 12 6 18 
%   TSH 0.0% 34.3% 54.5% 36.0% 
Total 
Count 4 35 11 50 
%   TSH 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=3.937 P=0.140 
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ABNORMAL THYROID PROFILE VS TYPE OF TREATMENT 
Table-13a 
Crosstab 
 FT3 Total 
LOW NORMAL HIGH 
TREATMENT 
IRREGULAR 
Count 7 4 2 13 
% within FT3 100.00% 9.76% 100.00% 26.00% 
REGULAR 
Count 0 37 0 37 
% within FT3 0.00% 90.24% 0.00% 74.00% 
Total 
Count 7 41 2 50 
% within FT3 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=31.238** P=0.001 
 
The above table indicates that abnormal T3 values are common in irregularly 
treated diabetic patients. The Chi-Square value is 31.238 which is highly 
significant. 
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Table-13b 
Crosstab 
 FT4 Total 
LOW NORMAL HIGH 
TREATMENT 
IRREGULAR 
Count 7 4 2 13 
% within FT4 100.00% 9.76% 100.00% 26.00% 
REGULAR 
Count 0 37 0 37 
% within FT4 0.00% 90.24% 0.00% 74.00% 
Total 
Count 7 41 2 50 
% within FT4 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=31.238** P=0.001 
The above table indicates that abnormal T4 level are common in 
irregularly treated diabetic patients. The Chi-Square value is 31.238 which is 
highly significant. 
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Table-13c 
Crosstab 
 TSH Total 
LOW NORMAL HIGH 
TREATMENT 
IRREGULAR 
Count 4 2 7 13 
% within TSH 100.00% 5.71% 63.64% 26.00% 
REGULAR 
Count 0 33 4 37 
% within TSH 0.00% 94.29% 36.36% 74.00% 
Total 
Count 4 35 11 50 
% within TSH 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=26.969**  P<0.001 
The above table indicates that abnormal TSH values are common in 
irregularly treated diabetic patients. The Chi-Square value is 26.969 which is 
highly significant. 
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DISCUSSION 
Diabetes mellitus is the most common endocrine disorder which 
involves multiple organ systems and leads to significant morbidity and 
mortality due to accompanying complications. Thyroid diseases are also a 
common endocrinopathy seen in the adult population. Thyroid hormones are 
intimately involved in cellular metabolism. Thus excess or deficit of either 
insulin or thyroid hormone could result in the functional derangement of the 
cellular metabolism. 
In the present study patients of diabetes mellitus were taken from 
Medical and Diabetic Outpatient Departments, Male & Female medical wards 
of Rajiv Gandhi Govt General Hospital and Madras Medical College (Chennai) 
over a period of 6 months from April 2018 to September 2018 and they were 
evaluated for altered thyroid profile. 
AGE DISTRIBUTION 
In the present study of 50 type 2 diabetic patients, , 4 patients (8%) were 
up to 40 years, , 36 patients (72%) were between 41-60 years and 10 patients 
(20%) were 61 years or more. This shows that the disease was more prevalent 
between 41-60 years of age. 
This observation was similar to WHO report which predicts that while 
the main increase in diabetes would be in the > 65 year age group in the 
developed countries, in India and developing countries the highest increase 
would occur in the age group of 45-65 year of age group.65 This observation is 
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also similar to Kapur et al , who reported that maximum number of cases were 
diagnosed between 40 and 59 year of age with no significant difference 
between the genders.66 
GENDER DISTRIBUTION 
In the present study among diabetic patients 52% (26 nos) of the studied 
population were males and 48%(24 nos) were females. Male: Female ratio is 
1.08:1 
This is similar to Jali et al68 and Flatau E et al69 who reported that 
diabetes was more prevalent in men than in women. 
DURATION OF DIABETES MELLITUS 
 In the present study, majority of cases that is 48% (24/50) had duration 
of diabetes upto 2-4 years, 14% (7/50) of patients had duration  upto 2 years 
and 38% (19/50) of patients had duration of illness more than 4 years. Majority 
of people are in the age group between 41 to 60 yrs and have duration of 
disease less than 4 years. 
FAMILY HISTORY OF DIABETES MELLITUS 
In the present study, 64% (32nos) of patients had family history of 
Diabetes and the remaining 36% (18nos) had no family history. This study is 
similar to that of Tattersal and Fojans75 and Vishwanthan.76 Vishwanthan et al 
conducted a study among 107 subjects. Out of 73 subjects who gave positive 
family history diabetes, 19 subjects (26%) later developed diabetes. 
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REGULARITY OF TREATMENT 
In the present study, Out of 50 subjects of the study group 74% (37/50) 
were on regular treatment and 26% (13/50) were on irregular treatment. Asha 
et al observed that 97% of type 2 diabetics were on antidiabetic agents and 
most were using them irregularly.77 Kaur et al observed that oral anti diabetic 
drug compliance rate was 62.9% in diabetic population.78  The difference in our 
study may be due to small sample size. 
ABNORMAL THYROID PROFILE 
In the present study, 30% (15) of the total 50 patients with diabetes 
mellitus had abnormal thyroid profile. The present study is similar to Vibha 
Uppal et al study of among the 120 diabetic subjects investigated, 17 % i.e. 20 
had hypothyroidism and 7.5 % i.e. 9 had hyperthyroidism. Thus a total of 24.5 
% patients showed thyroid disorder. 
       According to Asmabi Makandar et al study of among the 100 type 2 
diabetic patients studied, 32% of the patients had abnormal thyroid hormone 
levels and 68% had normal thyroid hormone levels. Among the 32% of 
diabetic patients with abnormal thyroid hormone levels, 22% of them had 
hypothyroidism – out of which 8% clinical hypothyroidism and 14% 
subclinical hypothyroidism.10% had hyperthyroidism – out of which 4% 
clinical hyperthyroidism and 6% subclinical hyperthyroidism. All the controls 
were found to have normal thyroid hormone levels. 
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 DISTRIBUTION OF THYROID ABNORMALITIES 
In the present study, 8% (4/50) of the patients had report suggestive of 
sub clinical hypothyroidism and 4% (2/50) of the patients had report suggestive 
of sub clinical hyperthyroidism,14%(7/50) of the patients had report suggestive 
of overt hypothyroidism,4%(2/50) of the patients had report suggestive of overt 
hyperthyroidism. 
             Celani MF et al in their study of 290 type 2 diabetes mellitus patients 
found that 91 patients(31.4%) had abnormal TSH concentrations out of which 
48.3% had subclinical hypothyroidism, 24.2% had subclinicl hyperthyroidism, 
23.1% had overt hypothyroidism and 4.4% had overt hyperthyroidism.55 
           In the present study, diabetic patients, when compared with the control 
group of normal patients in Whickham Study86  and a 20 years follow-up of 
whickham survey by Vanderpump MP et al87 shows that the prevalence of 
altered thyroid profile in the study group is significant (p=0.0064). 
The presence of altered thyroid profile in diabetic patients may be due to 
the fact that: 
In euthyroid individuals with diabetes mellitus, the serum T3 levels, 
basal TSH levels and TSH response to thyrotropin releasing hormone (TRH) 
may all be strongly influenced by the glycemic status.41 Poorly controlled 
diabetes may also result in impaired TSH response to TRH or loss of normal 
nocturnal TSH peak.43 It may be related to older age of the type 2 DM 
patients.64 
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SUMMARY 
 This study aimed at estimating the prevalence of thyroid dysfunction in 
type 2 Diabetes mellitus patients and also to find out it’s correlation with 
various risk factors. 
The study sample included 50 type 2 diabetic patients and 50 normal 
healthy control subjects presented in the wards and outpatients department. 
Each patient was assessed clinically and by laboratory investigations. 
Primary observations regarding thyroid profile in patients with type 2 
diabetes mellitus 
 In the present study, 30%(15 nos) of patients with type 2 diabetes 
mellitus had abnormal thyroid profile. 
 
 In patients with abnormal thyroid profile most common abnormality 
was Overt Hypothyroidism-7 out of 50(14%) followed by 
Subclinical Hypothyroidism-4 out of 50(8%), Overt 
Hyperthyroidism-2 out of 50(4%)  and  Subclinical Hyperthyroidism 
– 2 out of 50(4%). 
 
 Our study showed significant correlation between abnormal thyroid 
profile with regularity of treatment.Thyroid dysfunction is common 
among those who are irregularly treated for diabetes mellitus. 
 
 Diabetes mellitus and Thyroid dysfunction is common among 41-60 
years age group. 
  
 
 
 
CONCLUSION 
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CONCLUSION 
 Prevalence of thyroid dysfunction is more common among type 2 
diabetes mellitus patients than in general population. 
 
 The age group most commonly affected with diabetes mellitus and 
Thyroid dysfunction is 41-60 years. 
 
 Thyroid dysfunction is common in irregularly treated type 2 diabetic 
patients.  
 
 Routine screening for thyroid dysfunction in type 2 diabetes mellitus 
patients may be justified because overt Thyroid dysfunction is 
associated with significant morbidity including the adverse effects on 
glycemic control, lipid profile, bone mineral density and cardiovascular 
events. Regular treatment for diabetes mellitus may prevent Thyroid 
dysfunction. 
 
                                 
 
 
 
  
 
 
 
LIMITATIONS OF STUDY 
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LIMITATIONS 
 Study population was small. 
 Associated thyroid autoimmunity was not evaluated due to constraints. 
 So it was not able to refine the spectrum of thyroid dysfunction in type 2  
diabetics. 
 Follow up study was not done. So the natural history of subclinical 
thyroid dysfunction and it’s effect on various parameters could not be 
assessed. 
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PROFORMA 
NAME                                         : 
AGE/SEX                                    : 
IP/OP No.                                    : 
Occupation                                  : 
Address                                       : 
Contact No                                  : 
Patient Characteristics 
SYMPTOMS 
 Tiredness 
 Weakness 
 Hair loss 
 Constipation 
 Hoarseness of voice 
 Weight gain with poor appetite 
 Cold intolerance 
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 Menorrhagia /oligomenorrhea 
 Heat intolerance and sweating 
 Palpitations 
 Diarrhea 
 Polyuria 
 Weight loss with increased appetite 
PAST HISTORY 
 Diabetes mellitus 
 Renal disease 
 Liver disease 
 Hypertension 
 Thyroid dysfunction 
 Others 
MENSTRUAL HISTORY 
LMP: 
EXAMINATION 
 Pulse rate 
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 Blood Pressure 
 Respiratory rate 
 Temperature 
LABORATORY INVESTIGATIONS 
FBS    : 
PPBS    : 
Serum T3   : 
Serum T4   : 
Serrum TSH   : 
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INFORMATION SHEET 
We are conducting a study on “Thyroid dysfunction in Type 2 
diabetic patients and non diabetics”, among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your specimen may be 
valuable to us.    
        The purpose of this study is Thyroid dysfunction in type 2 diabetic 
patients is common among patients in our hospital. Methods to diagnose, 
monitor and prognosticate are non specific. There is a need to develop the 
parameters other than clinical in these patients for the better outcome. Fasting 
Blood  glucose ,Post prandial Blood Glucose and serum T3,T4 and TSH  levels 
appear to be good options in this aspect. 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do certain tests. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of Investigator     Signature of Participant  
Date: 
Place
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PATIENT CONSENT FORM 
Study Detail : “Prevalence of Thyroid dysfunction in type 2 diabetic 
patients and non diabetics” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction.   
b) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected.   
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
  
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arise from this study. 
d) I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or 
unusual symptoms.   
e) I hereby consent to participate in this study.   
f) I hereby give permission to undergo detailed clinical examination and 
blood investigations as required.   
 
 
Signature of investigator   Signature/Thumb impression 
Study investigator Name: 
Dr.K.MANIKANDAN 
 
Patient name and address: 
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1 45 M 136 208 8 25 0.05 YES 3 YES REGULAR
2 40 F 129 210 0.3 0.78 15.6 YES 5 YES REGULAR
3 55 M 127 220 3.9 1.1 8.6 YES 3 NO IRREGULAR
4 46 F 130 215 0.3 0.76 20.6 YES 4 YES REGULAR
5 50 F 128 226 2.3 0.47 23.5 YES 5 YES IRREGULAR
6 52 M 135 201 1.8 0.67 17.4 YES 4 NO IRREGULAR
7 47 M 140 240 0.3 0.6 15.7 YES 3 NO REGULAR
8 56 F 133 216 0.2 0.65 25.5 YES 6 NO REGULAR
9 37 M 127 243 0.3 0.56 18 YES 2 YES IRREGULAR
10 60 M 130 247 3.5 1.2 7.5 YES 7 YES REGULAR
11 58 F 150 267 9.4 27 0.031 YES 4 YES IRREGULAR
12 56 M 98 135 1.4 1.2 4.51 NO
13 49 M 97 130 1.9 1.5 4 NO
14 54 F 153 246 3.6 1.4 8.2 YES 5 NO IRREGULAR
15 44 F 95 127 4.5 1.2 3.6 NO
16 65 M 142 278 5.5 1.5 0.12 YES 7 YES REGULAR
17 62 M 90 132 4.2 1.3 3.5 NO
18 49 M 94 128 3.5 1.1 3.9 NO
19 38 F 92 125 5.8 1.6 4 NO
20 43 F 133 264 3.6 1 7.5 YES 3 NO REGULAR
21 61 M 138 204 3.5 1.4 3.2 YES 5 YES IRREGULAR
22 45 F 136 206 5.3 1.2 3.8 YES 4 NO IRREGULAR
23 51 M 88 127 4.5 1.5 2.4 NO
24 40 F 92 120 4 1.2 1.5 NO
25 54 M 129 206 3.9 1.1 2.5 YES 4 YES REGULAR
26 62 M 128 202 3.5 0.99 4.1 YES 7 YES REGULAR
27 43 F 130 210 4.6 1.3 0.18 YES 3 YES IRREGULAR
28 57 F 89 130 5.4 1.6 2.6 NO
29 64 M 128 236 4.2 0.99 3.4 YES 5 NO REGULAR
30 47 F 86 125 5.3 1.1 3.8 NO
31 42 F 92 132 4.5 1.5 2.6 NO
32 53 M 137 228 5.6 1.3 3.8 YES 3 YES REGULAR
33 62 F 130 239 3.8 0.95 2.1 YES 6 NO REGULAR
34 39 M 127 203 4.6 1.3 3.4 YES 2 YES REGULAR
35 55 F 134 213 5.6 1.4 4.1 YES 5 YES REGULAR
36 42 M 95 129 4.8 1.2 3.2 NO
37 51 F 84 126 5.3 0.98 3.9 NO
38 57 F 92 133 4.2 1.3 4.2 NO
39 49 M 86 128 3.8 1.5 3.2 NO
40 58 F 136 212 4.5 1.1 3.6 YES 6 NO REGULAR
41 52 M 129 204 5.6 0.99 2.8 YES 4 YES REGULAR
42 48 F 87 136 4.2 1.5 2.5 NO
43 45 M 92 130 4.6 1.6 3.3 NO
44 46 F 85 132 3.8 1.1 3.2 NO
45 50 M 92 128 6.2 1.5 1.5 NO
46 55 M 88 138 4.3 1 3.9 NO
47 47 F 130 220 5.3 1.2 3.5 YES 2 YES REGULAR
48 53 F 143 235 4.3 1.3 2.9 YES 4 YES REGULAR
49 50 M 92 130 3.7 1.5 4.1 NO
50 44 F 95 120 4.6 1.4 3.2 NO
51 45 M 87 127 3.7 0.97 2.7 NO
52 52 F 99 138 3.2 1.5 3.7 NO
53 42 M 84 132 4.8 1.1 3.2 NO
54 58 M 138 266 5.6 1.5 3.6 YES 4 YES REGULAR
55 59 F 144 240 3.4 1.3 2.4 YES 5 NO IRREGULAR
56 48 M 88 130 4.1 0.99 2.5 NO
57 47 F 90 137 5.2 1.4 2.8 NO
58 42 F 94 134 4.8 1.2 1.5 NO
59 52 M 138 243 5.8 1.5 3.9 YES 3 YES IRREGULAR
60 59 M 149 270 4.5 1.3 3.2 YES 5 NO REGULAR
61 45 F 83 136 5.7 1.2 3.5 NO
62 47 M 93 128 4.7 1.5 2.3 NO
63 54 F 90 130 3.8 1 3.5 NO
64 63 M 137 255 4.5 1.2 2.8 YES 7 NO REGULAR
65 65 F 143 264 3.7 1.6 3.6 YES 6 YES REGULAR
66 50 M 92 135 4 1.5 3.8 NO
67 46 F 98 138 3.7 1.7 2.3 NO
68 57 M 92 133 4.6 1.4 3.5 NO
69 53 F 97 138 5.6 1.3 2.4 NO
70 62 M 136 278 3.5 1.5 3.5 YES 5 NO REGULAR
71 54 F 140 240 4.5 1.4 2.6 YES 4 YES REGULAR
72 42 M 93 130 3.8 1.7 4.1 NO
73 49 F 96 138 4.6 1.2 3.4 NO
74 56 M 137 257 5.7 1.1 3.8 YES 3 YES REGULAR
75 50 F 128 246 3.9 1.4 2.6 YES 2 YES IRREGULAR
76 54 M 92 133 4.6 1.3 3.7 NO
77 46 F 96 128 5.6 1.2 3.7 NO
78 52 M 148 267 3.6 1.3 3.2 YES 3 YES REGULAR
79 58 F 139 257 3.8 1.6 2.4 YES 5 NO REGULAR
80 45 M 87 135 4.7 1.2 3.5 NO
81 48 M 95 129 5.5 1.5 2.8 NO
82 58 F 133 238 3.6 1.4 3.5 YES 4 YES IRREGULAR
83 43 M 140 250 4.5 1.2 2.7 YES 1 YES REGULAR
84 56 F 88 136 3.3 0.97 3.2 NO
85 48 M 93 127 4.6 0.96 4.1 NO
86 54 F 147 267 3.8 1.6 3.6 YES 1 YES REGULAR
87 65 M 152 270 3.7 1.3 3.7 YES 5 NO REGULAR
88 47 F 95 134 3.7 1.5 3.3 NO
89 38 M 87 130 4.5 1.1 2.5 NO
90 42 F 93 138 5.3 1.4 3.5 NO
91 45 M 94 137 4.6 1.3 4.1 NO
92 39 F 99 129 3.6 1.5 3.5 NO
93 49 M 82 128 4.5 1.3 2.5 NO
94 53 M 93 137 3.7 1.6 3.3 NO
95 63 M 138 246 3.8 1.5 3.4 YES 4 NO REGULAR
96 58 F 140 240 4.6 1.3 4.1 YES 3 YES REGULAR
97 50 M 133 236 5.6 1.6 3.7 YES 3 NO REGULAR
98 39 F 129 231 4.6 1.5 2.5 YES 2 YES REGULAR
99 44 M 139 245 3.5 1.1 3.2 YES 4 YES REGULAR
100 51 F 140 230 4.8 1.6 3.6 YES 3 YES REGULAR
